Department of Applied Biology, CSIR-Indian Institute of Chemical Technology, Hyderabad 500007, India; Academy of Scientific and Innovative Research, Ghaziabad 201002, India.
Academy of Scientific and Innovative Research, Ghaziabad 201002, India; Department of Organic Synthesis and Process Chemistry, CSIR-Indian Institute of Chemical Technology, Hyderabad 500007, India.
Int Immunopharmacol. 2023 Nov;124(Pt B):111070. doi: 10.1016/j.intimp.2023.111070. Epub 2023 Oct 18.
Mitochondrial dysfunction due to deregulated production of mitochondria-derived ROS is implicated in the development and progression of non-alcoholic fatty liver disease (NAFLD) to non-alcoholic steatohepatitis (NASH). Recently, we synthesized a novel mitochondria-targeted esculetin (Mito-Esc) and investigated its dose-response therapeutic efficacy in mitigating high-fat diet (HFD)-induced NAFLD and NASH in Apoe mice. Mito-Esc administration, compared to simvastatin and pioglitazone, dose-dependently caused a significant reduction in body weight, improved lipid profile, glucose homeostasis, and pro-inflammatory cytokines level. Mito-Esc administration reduced adipose tissue hypertrophy and lipid accumulation presumably by regulating the levels of CD36, PPAR-γ, EBP-α, and their target genes. Mechanistically, Mito-Esc-induced activation of the AMPK1α-SIRT1 axis inhibited pre-adipocyte differentiation. Conversely, Mito-Esc failed to regulate pre-adipocyte differentiation under AMPK/SIRT1 depleted conditions. In parallel, Mito-Esc administration ameliorated HFD-induced steatosis, fibrosis of the liver, and NAFLD-associated atheromatous plaque formation in the aorta. Importantly, Mito-Esc administration inhibited HFD-induced infiltration of macrophages, a marker of steatohepatitis, in the adipose and liver tissues. The results of the in vitro studies showed that Mito-Esc treatment significantly inhibits TGF-β-induced hepatic stellate cell differentiation as well as the fibrotic markers. Consistent with the above observations, Mito-Esc treatment by activating the AMPK-SIRT1 pathway markedly reversed palmitate-induced mitochondrial superoxide production, depolarization of mitochondrial membrane potential, and lipid accumulation in HepG2 cells. Together, the therapeutic efficacy of Mito-Esc in the mitigation of HFD-induced lipotoxicity, and the associated NASH is in part, mediated by potentiating the AMPK-SIRT1 axis.
线粒体功能障碍是由于线粒体来源的 ROS 产生失调而导致的,与非酒精性脂肪性肝病(NAFLD)向非酒精性脂肪性肝炎(NASH)的发展和进展有关。最近,我们合成了一种新型的线粒体靶向七叶灵(Mito-Esc),并研究了其在减轻载脂蛋白 E 基因敲除(Apoe)小鼠高脂饮食(HFD)诱导的 NAFLD 和 NASH 中的剂量反应治疗效果。与辛伐他汀和吡格列酮相比,Mito-Esc 给药剂量依赖性地显著降低体重、改善血脂谱、葡萄糖稳态和促炎细胞因子水平。Mito-Esc 给药减少脂肪组织肥大和脂质积累,可能是通过调节 CD36、PPAR-γ、EBP-α 及其靶基因的水平来实现的。从机制上讲,Mito-Esc 诱导的 AMPK1α-SIRT1 轴的激活抑制了前脂肪细胞的分化。相反,在 AMPK/SIRT1 耗尽的情况下,Mito-Esc 未能调节前脂肪细胞的分化。与此同时,Mito-Esc 给药改善了 HFD 诱导的肝脏脂肪变性、纤维化和主动脉中与 NAFLD 相关的动脉粥样硬化斑块形成。重要的是,Mito-Esc 给药抑制了 HFD 诱导的脂肪组织和肝脏组织中巨噬细胞的浸润,巨噬细胞是 steatohepatitis 的标志物。体外研究的结果表明,Mito-Esc 治疗显著抑制 TGF-β诱导的肝星状细胞分化以及纤维化标志物。与上述观察结果一致,Mito-Esc 通过激活 AMPK-SIRT1 通路治疗可显著逆转棕榈酸诱导的 HepG2 细胞中线粒体超氧化物产生、线粒体膜电位去极化和脂质积累。总之,Mito-Esc 在减轻 HFD 诱导的脂毒性和相关 NASH 方面的治疗效果,部分是通过增强 AMPK-SIRT1 轴来介导的。